Abstract:The current global COVID-19 pandemic is caused by beta coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), which already infected over 10 million and caused 500 thousand deaths by June 2020. Overproduction of cytokines triggered by COVID-19 infection, known as "cytokine storm", is a highly risk factor associated with disease severity. However, how COVID-19 infection induce cytokine storm is still largely unknown. Accumulating in vitro and in vivo evidence suggests that gut is also susceptible to COVID19 infection: Human intestinal organoids, an in vitro model which mimic the specific cell type and spatial structure of the intestine, were susceptible to SARS-CoV2 infection; A significant fraction of patients reported gut symptoms; Viral RNA may persist for more than 30 days and infectious virus could be isolated in fecal samples. The gastrointestinal tract is the primary site of interaction between the host immune system with symbiotic and pathogenic microorganisms. The bacteria resident in our gastrointestinal tract, known as gut microbiota, is important to maintain the homeostasis of our immune system. While imbalance of gut microbiota, or dysbiosis, is associated with multiple inflammation diseases5. It's possible that SARS-CoV-2 infection may lead to alternation of gut microbiota thus worsen the host symptom. IL-18 is a proinflammatory cytokine produced multiple enteric cells, including intestinal epithelial cells (IECs), immune cells as well as enteric nervous system, and was shown to increase in the serum of COVID-19 patients. Immunoglobin A (IgA) is mainly produced in the mucosal surfaces, in humans 40-60mg kg-1 day-1 than all other immunoglobulin isotypes combined, and at least 80% of all plasma cells are located in the intestinal lamina propria. Recent study showed that SARS-CoV-2 specific IgA in the serum is positively correlate with the disease severity in COVID-19 patients11. Here we investigated the alterations of microbiota in COVID-19 patients, and its correlation with inflammatory factor IL-18 and SARS-CoV2 specific IgA. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by a grant from the National Key R&D Program of China (2018YFA0508000) (SZ), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29030101) (SZ), the National Natural Science Foundation of China (81822021, 91842105, 31770990, 81821001) (SZ), and the Fundamental Research Funds for the Central Universities (WK2070000159) (SZ). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This is an observational cohort study. This study is part of the project of "Construction of a bio-information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui" (ChiCTR2000030331). This study was approved by the institutional board of the First Affiliated Hospital of University of Science and Technology of China (2020-XG(H)-009). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available upon request.

Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity

Gut Microbiota Improves Prognostic Prediction in Critically Ill COVID-19 Patients Alongside Immunological and Hematological Indicators

Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Fatality in COVID-19 Patients

Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza.

Gut Mycobiota Alterations in Patients with COVID-19 and H1N1 Infections and Their Associations with Clinical Features

Gut microbiota composition is associated with disease severity and host immune responses in COVID-19

Gut mycobiota alterations in patients with COVID-19 and H1N1 and associations with immune and gastrointestinal symptoms

The Faecal Metabolome in COVID-19 Patients is Altered and Associated with Clinical Features and Gut Microbes

Analysis of the Intestinal Microbiota in COVID-19 Patients and Its Correlation with the Inflammatory Factor IL-18

Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization

Explore the changes of intestinal flora in patients with coronavirus disease 2019 based on bioinformatics

Dynamic Alterations in the Respiratory Tract Microbiota of Patients with COVID‐19 and its Association with Microbiota in the Gut

Gut Microbiota Imbalance in Colorectal Cancer Patients, the Risk Factor of COVID-19 Mortality

Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization

Lymphocyte and neutrophil count combined with intestinal bacteria abundance predict the severity of COVID-19

Potential Associations Between Microbiome and COVID-19

Gut microbiota in COVID-19: new insights from inside

Analysis of the intestinal microbiota in COVID 19 patients and its correlation with the inflammatory factor IL 18 and SARS CoV 2 specific IgA

Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases

Comparison of the respiratory tract microbiome in hospitalized COVID‐19 patients with different disease severity

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19